O
EPIX

OrbiMed’s ESSA Pharma EPIX Stock Holding History

OrbiMed’s Portfolio EPIX Stock Details EPIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-842,366
Closed -$2.6M – 121
2023
Q3 		$2.6M Sell
842,366
-79,574
-9% -$229K 0.06% 108
2023
Q2 		$2.49M Sell
921,940
-276,397
-23% -$810K 0.05% 113
2023
Q1 		$3.56M Buy
1,198,337
+833,037
+228% +$2.45M 0.07% 110
2022
Q4 		$921K Sell
365,300
-275,345
-43% -$790K 0.02% 111
2022
Q3 		$1.17M Buy
+640,645
New +$1.69M 0.02% 125
2021
Q1 		– Sell
-460,500
Closed -$5.49M – 168
2020
Q4 		$5.49M Sell
460,500
-716,983
-61% -$5.05M 0.05% 138
2020
Q3 		$8.13M Sell
1,177,483
-294,370
-20% -$2M 0.1% 113
2020
Q2 		$9.13M Hold
1,471,853
– – 0.13% 103
2020
Q1 		$5.89M Hold
1,471,853
– – 0.1% 101
2019
Q4 		$8.1M Hold
1,471,853
– – 0.12% 87
2019
Q3 		$4.96M Buy
+1,471,853
New +$3.63M 0.09% 95

Other funds holding EPIX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

OrbiMed's EPIX Position: Q4 2023 in Review

OrbiMed sold out of ESSA Pharma (EPIX) in Q4 2023, closing a stake of 842,366 shares — an estimated $2.6M sold.

OrbiMed first reported a position in EPIX in Q3 2019 and held it in 11 quarters. The position peaked at $9.13M in Q2 2020. 31 funds tracked by Wall St. Rank hold EPIX as of Q4 2023.

  • OrbiMed reported no remaining ESSA Pharma position as of Q4 2023 after selling out during the quarter.
  • OrbiMed sold 842,366 ESSA Pharma shares in Q4 2023, an estimated $2.6M.
  • OrbiMed first reported a position in ESSA Pharma in Q3 2019 and held it in 11 quarters.
  • OrbiMed's ESSA Pharma position peaked at $9.13M in Q2 2020.
  • 31 funds tracked by Wall St. Rank held ESSA Pharma as of Q4 2023.

Based on OrbiMed's 13F filing for Q4 2023, filed 14 Feb 2024.